DNA methylation profiles in chronic lymphocytic leukemia
patients treated with chemoimmunotherapy

J 2019

DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy

TSAGIOPOULOU, M., N. PAPAKONSTANTINOU, T. MOYSIADIS, L. MANSOURI, V. LJUNGSTROM et. al.

Základní údaje

Originální název

DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy

Autoři

TSAGIOPOULOU, M. (300 Řecko), N. PAPAKONSTANTINOU (300 Řecko), T. MOYSIADIS (300 Řecko), L. MANSOURI (752 Švédsko), V. LJUNGSTROM (752 Švédsko), M. DURAN-FERRER (724 Španělsko), A. MALOUSI (300 Řecko), A.C. QUEIROS (724 Španělsko), Karla PLEVOVÁ (203 Česká republika, domácí), S. BHOI (752 Švédsko), P. KOLLIA (300 Řecko), D. OSCIER (826 Velká Británie a Severní Irsko), A. ANAGNOSTOPOULOS (300 Řecko), L. TRENTIN (380 Itálie), M. RITGEN (276 Německo), Šárka POSPÍŠILOVÁ (203 Česká republika, garant, domácí), N. STAVROYIANNI (300 Řecko), P. GHIA (380 Itálie), J.I. MARTIN-SUBERO (724 Španělsko), C. POTT (380 Itálie), R. ROSENQUIST (752 Švédsko) a K. STAMATOPOULOS (300 Řecko)

Vydání

CLINICAL EPIGENETICS, LONDON, BMC, 2019, 1868-7075

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.028

Kód RIV

RIV/00216224:14740/19:00113009

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1186/s13148-019-0783-1

UT WoS

000501362500005

Klíčová slova anglicky

DNA methylation; Chemoimmunotherapy; CLL; Microarray analysis; Relapse

Štítky

14110212, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 2. 2020 14:45, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Background In order to gain insight into the contribution of DNA methylation to disease progression of chronic lymphocytic leukemia (CLL), using 450K Illumina arrays, we determined the DNA methylation profiles in paired pre-treatment/relapse samples from 34 CLL patients treated with chemoimmunotherapy, mostly (n = 31) with the fludarabine-cyclophosphamide-rituximab (FCR) regimen. Results The extent of identified changes in CLL cells versus memory B cells from healthy donors was termed "epigenetic burden" (EB) whereas the number of changes between the pre-treatment versus the relapse sample was termed "relapse changes" (RC). Significant (p < 0.05) associations were identified between (i) high EB and short time-to-first-treatment (TTFT); and, (ii) few RCs and short time-to-relapse. Both the EB and the RC clustered in specific genomic regions and chromatin states, including regulatory regions containing binding sites of transcription factors implicated in B cell and CLL biology. Conclusions Overall, we show that DNA methylation in CLL follows different dynamics in response to chemoimmunotherapy. These epigenetic alterations were linked with specific clinical and biological features.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

Citovat

TSAGIOPOULOU, M., N. PAPAKONSTANTINOU, T. MOYSIADIS, L. MANSOURI, V. LJUNGSTROM, M. DURAN-FERRER, A. MALOUSI, A.C. QUEIROS, Karla PLEVOVÁ, S. BHOI, P. KOLLIA, D. OSCIER, A. ANAGNOSTOPOULOS, L. TRENTIN, M. RITGEN, Šárka POSPÍŠILOVÁ, N. STAVROYIANNI, P. GHIA, J.I. MARTIN-SUBERO, C. POTT, R. ROSENQUIST a K. STAMATOPOULOS. DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy. CLINICAL EPIGENETICS. LONDON: BMC, 2019, roč. 11, č. 1, s. 177-188. ISSN 1868-7075. Dostupné z: https://dx.doi.org/10.1186/s13148-019-0783-1.

@article{1625079,
   author = {Tsagiopoulou, M. and Papakonstantinou, N. and Moysiadis, T. and Mansouri, L. and Ljungstrom, V. and DuranandFerrer, M. and Malousi, A. and Queiros, A.C. and Plevová, Karla and Bhoi, S. and Kollia, P. and Oscier, D. and Anagnostopoulos, A. and Trentin, L. and Ritgen, M. and Pospíšilová, Šárka and Stavroyianni, N. and Ghia, P. and MartinandSubero, J.I. and Pott, C. and Rosenquist, R. and Stamatopoulos, K.},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s13148-019-0783-1},
   keywords = {DNA methylation; Chemoimmunotherapy; CLL; Microarray analysis; Relapse},
   language = {eng},
   issn = {1868-7075},
   journal = {CLINICAL EPIGENETICS},
   title = {DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy},
   url = {https://clinicalepigeneticsjournal.biomedcentral.com/track/pdf/10.1186/s13148-019-0783-1},
   volume = {11},
   year = {2019}
}

TY  - JOUR
ID  - 1625079
AU  - Tsagiopoulou, M. - Papakonstantinou, N. - Moysiadis, T. - Mansouri, L. - Ljungstrom, V. - Duran-Ferrer, M. - Malousi, A. - Queiros, A.C. - Plevová, Karla - Bhoi, S. - Kollia, P. - Oscier, D. - Anagnostopoulos, A. - Trentin, L. - Ritgen, M. - Pospíšilová, Šárka - Stavroyianni, N. - Ghia, P. - Martin-Subero, J.I. - Pott, C. - Rosenquist, R. - Stamatopoulos, K.
PY  - 2019
TI  - DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy
JF  - CLINICAL EPIGENETICS
VL  - 11
IS  - 1
SP  - 177
EP  - 177
PB  - BMC
SN  - 18687075
KW  - DNA methylation
KW  - Chemoimmunotherapy
KW  - CLL
KW  - Microarray analysis
KW  - Relapse
UR  - https://clinicalepigeneticsjournal.biomedcentral.com/track/pdf/10.1186/s13148-019-0783-1
L2  - https://clinicalepigeneticsjournal.biomedcentral.com/track/pdf/10.1186/s13148-019-0783-1
N2  - Background In order to gain insight into the contribution of DNA methylation to disease progression of chronic lymphocytic leukemia (CLL), using 450K Illumina arrays, we determined the DNA methylation profiles in paired pre-treatment/relapse samples from 34 CLL patients treated with chemoimmunotherapy, mostly (n = 31) with the fludarabine-cyclophosphamide-rituximab (FCR) regimen. Results The extent of identified changes in CLL cells versus memory B cells from healthy donors was termed "epigenetic burden" (EB) whereas the number of changes between the pre-treatment versus the relapse sample was termed "relapse changes" (RC). Significant (p < 0.05) associations were identified between (i) high EB and short time-to-first-treatment (TTFT); and, (ii) few RCs and short time-to-relapse. Both the EB and the RC clustered in specific genomic regions and chromatin states, including regulatory regions containing binding sites of transcription factors implicated in B cell and CLL biology. Conclusions Overall, we show that DNA methylation in CLL follows different dynamics in response to chemoimmunotherapy. These epigenetic alterations were linked with specific clinical and biological features.
ER  -

TSAGIOPOULOU, M., N. PAPAKONSTANTINOU, T. MOYSIADIS, L. MANSOURI, V. LJUNGSTROM, M. DURAN-FERRER, A. MALOUSI, A.C. QUEIROS, Karla PLEVOVÁ, S. BHOI, P. KOLLIA, D. OSCIER, A. ANAGNOSTOPOULOS, L. TRENTIN, M. RITGEN, Šárka POSPÍŠILOVÁ, N. STAVROYIANNI, P. GHIA, J.I. MARTIN-SUBERO, C. POTT, R. ROSENQUIST a K. STAMATOPOULOS. DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy. \textit{CLINICAL EPIGENETICS}. LONDON: BMC, 2019, roč.~11, č.~1, s.~177-188. ISSN~1868-7075. Dostupné z: https://dx.doi.org/10.1186/s13148-019-0783-1.

Podrobný výpis o publikaci